Search

It’s easy to produce papers and make recommendations, says former Finnish prime minister Esko Aho. Now we need practical results.

YouTube, MySpace – those are some of the hottest properties on the Internet these days. They may also be the working definition of demand-side innovation,

European pharma and biotech companies are behind the US. But in one shining area, Europe has outpaced the US in creating a new sector: biosimilars.

The latest buzzword among Brussels technocrats is “lead markets”. And it’s going to be put into action, on an experimental basis, in 2007.

2006 was a record year for business start-ups in Ireland.

The value of R&D coming out of US universities is increasing. And the question of exactly how Europe measures up in comparison may soon be answered.

The Drugs for Neglected Diseases initiative launched its first product, a new formulation of for treating malaria.

The UK’s two major public funders of stem cell research are to run a national public discussion about the controversial field of stem cell research.

The band of UK quoted tech commercialisation companies has another member. Ipso Ventures joined the AIM market, raising £4.5 million.

Innovation policy is hot in Brussels, says Science|Business editor Richard L. Hudson. Hot enough for so a confusing array of proposals, white papers, conferences and task forces.